Press release
Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Alector, Amylyx, Annexon, Apellis, Cellenkos, Covis, Cytokinetics, Kadimastem, Prileni
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 90+ key pharma and biotech companies are working on 100+ pipeline drugs in the Amyotrophic Lateral Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years."Amyotrophic Lateral Sclerosis (ALS) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Therapeutics Market.
The report provides a detailed description of the Amyotrophic Lateral Sclerosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Amyotrophic Lateral Sclerosis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Amyotrophic Lateral Sclerosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Amyotrophic Lateral Sclerosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Amyotrophic Lateral Sclerosis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Amyotrophic Lateral Sclerosis Therapeutics Domain @
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Amyotrophic Lateral Sclerosis (ALS) Therapeutics Analysis
Currently, there is no cure for ALS and no effective treatment to halt, or reverse, the progression of the disease. The treatment landscape of ALS includes multidisciplinary care, such as physical therapy, speech therapy, dietary counselling, heat or whirlpool therapy and others. Moreover, there are five drugs approved by the US FDA to treat ALS, namely RELYVRIO, Riluzole, NUEDEXTA, RADICAVA (IV and oral), and TIGLUTIK. Medications are also prescribed to help manage symptoms of ALS, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar affect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs are also available to help individuals with pain, depression, sleep disturbances, and constipation.
In September 2022, the FDA approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for treating adults with ALS. RELYVRIO (previously known as AMX0035 in the US). In May 2022, the oral formulation RADICAVA ORS (edaravone) was approved by the US FDA for treating ALS.
To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Amyotrophic Lateral Sclerosis. Currently, Biogen is leading the therapeutics market with its Amyotrophic Lateral Sclerosis drug candidates in the most advanced stage of clinical development.
Amyotrophic Lateral Sclerosis (ALS) Companies in the Therapeutics Market Include:
AB Science, AbbVie, AI Therapeutics, Inc., AL-S Pharma, Alector Inc., Amylyx Pharmaceuticals, Annexon, Inc., Apellis Pharmaceuticals, Inc., Aquestive Therapeutics, Ashvattha Therapeutics, Inc., Avanir Pharmaceuticals (a subsidiary of Otsuka America), Biogen, Biohaven Pharmaceuticals, Brainstorm Cell Therapeutics, Calico Life Sciences LLC, Cellenkos, Clene Nanomedicine Biosciences, Corcept Therapeutics, Covis, Cytokinetics, Cytokinetics/Astellas Pharma, Denali Therapeutics Inc., DS Pharma, Eledon Pharmaceuticals, Ferrer Internacional S.A., Genuv Inc., Helixmith Co., Ltd., InFlectis BioScience, Ionis Pharmaceuticals, Kadimastem, Knopp Biosciences, MediciNova, Mitsubishi Tanabe Pharma Corporation, Molecular Partners, NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Prilenia Therapeutics, Procypra Therapeutics, PTC Therapeutics, QurAlis Corporation, Ra Pharmaceuticals, Rapa Therapeutics LLC, Retrotope, Inc., Revalesio Corporation, Sanofi, PTC Therapeutics, Seelos Therapeutics, UCB Pharma, Woolsey Pharmaceuticals, ZZ Biotech, LLC, and many others.
Emerging and Marketed Amyotrophic Lateral Sclerosis Therapies Covered in the Report Include:
• AMX0035: Amylyx Pharmaceuticals
• ANX005: Annexon
• Exservan: Aquestive Therapeutics
• ION363: Ionis Pharmaceuticals
• Mastitis (AB Sciences
• Nuedexta: Avanir Pharmaceuticals
• Radicava: Mitsubishi Tanabe Pharma Corporation
• RNS60: Revalesio Corporation
• Tiglutik/ Teglutik: ITF Pharma
• Tofersen: Biogen/Ionis Pharmaceuticals
• Verdiperstat: Biohaven
And Many More
Get an in-depth Assessment of the Emerging Therapies and Amyotrophic Lateral Sclerosis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Amyotrophic Lateral Sclerosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Amyotrophic Lateral Sclerosis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Current Treatment Patterns
4. Amyotrophic Lateral Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis Late-Stage Products (Phase-III)
7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Amyotrophic Lateral Sclerosis Discontinued Products
13. Amyotrophic Lateral Sclerosis Product Profiles
14. Amyotrophic Lateral Sclerosis Companies
15. Amyotrophic Lateral Sclerosis Drugs
16. Dormant and Discontinued Products
17. Amyotrophic Lateral Sclerosis Unmet Needs
18. Amyotrophic Lateral Sclerosis Future Perspectives
19. Amyotrophic Lateral Sclerosis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research
Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices
Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology
Other Trending Healthcare Reports by DelveInsight
Aneurysmal Subarachnoid Hemorrhage (SAH) Market
https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
Dupuytren's Disease Market
https://www.delveinsight.com/report-store/dupuytrens-disease-market
Homocystinuria Market
https://www.delveinsight.com/report-store/homocystinuria-market-new
Platinum-Resistant Relapsed Ovarian Cancer Market
https://www.delveinsight.com/report-store/platinum-resistant-relapsed-ovarian-cancer-market
Dementia with Diabetes Market
https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast
Pyruvate Kinase Deficiency Market
https://www.delveinsight.com/report-store/pyruvate-kinase-deficiency-market
Uterine Serous Carcinoma Market
https://www.delveinsight.com/report-store/uterine-serous-carcinoma-market
Paraganglioma Market
https://www.delveinsight.com/report-store/paraganglioma-market
Spinal Cord Stimulators (SCS) Global Market
https://www.delveinsight.com/report-store/spinal-cord-stimulator-market
Adult Spinal Deformity Market
https://www.delveinsight.com/report-store/adult-spinal-deformity-market
Age-related Vision Dysfunction Market
https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market
Erythropoietic Protoporphyria Market
https://www.delveinsight.com/report-store/erythropoietic-protoporphyria-market
Juvenile Idiopathic arthritis (JIA) Market
https://www.delveinsight.com/report-store/juvenile-idiopathic-arthritis-jia-market
Otoscope Market
https://www.delveinsight.com/report-store/otoscope-market
Surgical Energy Generators Market
https://www.delveinsight.com/report-store/surgical-energy-generators-market
Eosinophilic Esophagitis Market
https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market
Hypereosinophilic Syndrome Market
https://www.delveinsight.com/report-store/hypereosinophilic-syndrome-market
Campylobacter Infections Market
https://www.delveinsight.com/report-store/campylobacter-infections-market
Degenerative Disc Disease Market
https://www.delveinsight.com/report-store/degenerative-disc-disease-ddd-market
Optic Neuritis Market
https://www.delveinsight.com/report-store/optic-neuritis-market
Shoulder Replacement Devices Global Market
https://www.delveinsight.com/report-store/shoulder-replacement-devices-market
Scleritis Market
https://www.delveinsight.com/report-store/scleritis-market
Polypoidal Choroidal Vasculopathy (PCV) Market
https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
Post-Polycythemia Vera Myelofibrosis Market
https://www.delveinsight.com/report-store/post-polycythemia-vera-myelofibrosis-market
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Market
https://www.delveinsight.com/report-store/severe-acute-respiratory-syndrome-sars-coronavirus-infection-market
Cardiac Biomarkers Testing Devices Global Market
https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market
Graves Orbitopathy Market
https://www.delveinsight.com/report-store/graves-orbitopathy-market
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market
https://www.delveinsight.com/report-store/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Febrile Neutropenia Market
https://www.delveinsight.com/report-store/febrile-neutropenia-market
Axial Spondyloarthritis Market
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market
Conductive Hearing Loss Market
https://www.delveinsight.com/report-store/conductive-hearing-loss-market
Metastatic Cutaneous Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/metastatic-cutaneous-squamous-cell-carcinoma-market
Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market
Schistosomiasis Market
https://www.delveinsight.com/report-store/schistosomiasis-market
Adenosine Deaminase-Severe Combined Immunodeficiency Market
https://www.delveinsight.com/report-store/adenosine-deaminase-severe-combined-immunodeficiency-market
Dermal Erythema Market
https://www.delveinsight.com/report-store/dermal-erythema-market
Hypercalcemia Market
https://www.delveinsight.com/report-store/hypercalcemia-market
Marginal Zone Lymphoma Market
https://www.delveinsight.com/report-store/marginal-zone-lymphoma-market
Tonsillitis Market
https://www.delveinsight.com/report-store/tonsillitis-marke
Biliary Atresia Market
https://www.delveinsight.com/report-store/biliary-atresia-market
Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market
Retinoblastoma Market
https://www.delveinsight.com/report-store/retinoblastoma-market
Dysautonomia (Autonomic Dysfunction) Market
https://www.delveinsight.com/report-store/dysautonomia-autonomic-dysfunction-market
IgA Nephropathy (IgAN) Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
Kyphoscoliosis Market
https://www.delveinsight.com/report-store/kyphoscoliosis-market
Myofascial Pain Syndrome Market
https://www.delveinsight.com/report-store/myofascial-pain-syndrome-market
Osteogenesis Imperfecta Market
https://www.delveinsight.com/report-store/osteogenesis-imperfecta-oi-market
Treatment-Resistant Depression (TRD) Market
https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market
Fallopian Tube Cancer Market
https://www.delveinsight.com/report-store/fallopian-tube-cancer-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Alector, Amylyx, Annexon, Apellis, Cellenkos, Covis, Cytokinetics, Kadimastem, Prileni here
News-ID: 3309403 • Views: …
More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…

Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…

Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…

Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Amyotrophic
Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment Report 2024 (Upda …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
Amyotrophic Lateral Sclerosis Pipeline Insights and Treatment Drugs 2024 (Update …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
Amyotrophic Lateral Sclerosis Pipeline Therapeuetics Report 2024
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
Amyotrophic Lateral Sclerosis (ALS) Market Size, Trends & Share 2034
Market Overview:
The Amyotrophic Lateral Sclerosis (ALS) market reached a value of US$ 494.1 Million in 2023 and expected to reach US$ 715.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.4% during 2024-2034.
The report offers a comprehensive analysis of the amyotrophic lateral sclerosis market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available…
Amyotrophic Lateral Sclerosis Pipeline Insight Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Amyotrophic Lateral Sclerosis Pipeline constitutes 90+ key companies continuously working towards developing 100+ Amyotrophic Lateral Sclerosis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Amyotrophic Lateral Sclerosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Amyotrophic…
Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
The global market for amyotrophic lateral sclerosis devices or motor neuron disease devices anticipated to reach $19.5 billion by 2029, growing at a CAGR of 7.3% over the forecast period, driven by increasing incidence, rising geriatric population, lack of curative treatment, growing public awareness, and technological advancements in palliative care.
https://www.ihealthcareanalyst.com/global-amyotrophic-lateral-sclerosis-devices-market/
Amyotrophic lateral sclerosis or Lou Gehrig's disease or motor neuron disease (MND) is characterized by progressive degeneration of the motor nerve…